Clinical presentation, diagnostic findings and management of cerebral ischemic events in patients on treatment with non-vitamin K antagonist oral anticoagulants – A systematic review

Thomas Raphael Meinel1*, Sebastien Frey1, Marcel Arnold1, Sarah Kendroud2, Urs Fischer1, Johannes Kaesmacher3, Mirjam Rachel Heldner1, Simon Jung1

1 Department of Neurology, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland, 2 Department of Neurology, Touro University California, Vallejo, California, United States of America, 3 Department of Diagnostic and Interventional Neuroradiology, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland

* thomas.meinel@insel.ch

Abstract

Background
Non-vitamin K antagonist oral anticoagulants (NOAC) are equally or potentially superior in terms of effectiveness in the prevention of ischemic stroke and carry a lower associated risk of intracranial hemorrhage compared to Vitamin K antagonists. Nevertheless, ischemic strokes also occur in patients who are being treated with NOAC. In those particular patients, knowledge about the underlying stroke etiology, clinical presentation, acute management, and complication rates is scarce.

Objective
Systematic literature review to provide a comprehensive clinical overview in terms of presentation, laboratory, imaging parameters and outcomes of patients suffering from acute cerebral ischemic events (i.e. TIA and acute ischemic stroke) while on treatment with a NOAC. Only if available, comparison to VKA is presented which was not the primary focus of this analysis.

Data sources
PubMed/MEDLINE, Scopus and EMBASE from January 1, 2006, to November 20, 2018.

Study eligibility criteria
52 studies providing detailed information on a total of 12247 patients were included. We excluded case reports and case series with less than five patients.
Study appraisal and synthesis method
We systematically assessed study quality using a bias tool and pooled consistent data.

Results
Existing data indicates milder stroke severity and smaller infarct size of acute ischemic stroke on treatment with NOAC compared to stroke occurrence on Vitamin K antagonists (VKA). Established risk factors for ischemic events also play a role in stroke while on NOACs, albeit the underlying etiology remains poorly understood. Intravenous thrombolysis and endovascular therapy seem to be safe and effective, but patient selection for recanalization therapies is challenging.

Limitations
Limited quality of published data, duplicate cases, statistical issues of data pooling, possible incomplete retrieval of identified research and reporting bias might have limited our findings.

Conclusions
Acute ischemic events despite treatment with NOAC therapy are insufficiently investigated.

Systematic review registration number
PROSPERO: CRD42018074853.

Introduction
Rationale
The introduction of rivaroxaban in 2008 and the subsequent addition of three more non-vitamin K antagonist oral anticoagulants (NOAC) had an enormous impact on the primary and secondary prevention of acute ischemic stroke (AIS) in the setting of nonvalvular atrial fibrillation (AF). Most guidelines now recommend NOAC over vitamin K antagonists (VKA) with a class I recommendation level [1–4]. The net clinical benefit arises mainly from a reduced risk of intracerebral hemorrhage (ICH) with NOAC treatment, whereas the prevention of AIS or TIA, which are later in this review referred to as acute ischemic events (AIE), is equal or better compared to VKA treatment. Nevertheless, 1–2% of patients per year suffer from an AIE while on NOAC treatment [5]. The knowledge about stroke subtype, vessel occlusion location, pattern of cerebral infarction, complications and therapy strategies in those patients is scarce. Identifying factors that are associated with AIE that occur while on NOAC treatment may improve individualized treatment decisions. Furthermore, it is important to analyze the reasons for NOAC failure in real-life data, because randomized-controlled trials represent a highly selective patient population. For example an additional indication for anticoagulation, chronic non-steroidal anti-inflammatory drug therapy, severe chronic renal insufficiency, anemia, unreliability or short life expectancy (e.g. malignancy) were exclusion criteria in the pivotal phase III trials, but are likely to be present in NOAC real-life patients [6–9].
Objectives

We aimed to provide a comprehensive clinical overview (clinical presentation, laboratory, imaging parameters and outcomes) of AIE in patients on NOAC treatment by performing a systematic review of the current literature. Only if available, comparison to VKA is presented which was not the primary focus of this analysis.

Methods

Protocol and registration

The study protocol has been published prior to performing the study (PROSPERO: CRD42018074853).

Eligibility criteria

Eligible studies included all age groups and all ethnic groups with given demographic, clinical, laboratory or imaging information on NOAC patients in the setting of AIE. We included all evaluative methodologies. Since the first NOAC, rivaroxaban, entered the market in 2008, we only considered publications beyond January 1st, 2006 for analysis. We excluded studies with no specific characterization of patients who suffered an AIE while taking NOAC. We excluded case reports and case series with less than five patients.

Information sources

Data for this review was identified via a search on MEDLINE, PubMed, Scopus and Embase and references from relevant articles using the search terms “DOAC” OR “NOAC” OR “anticoagulation”, and “ischemic stroke” or “TIA”. Only articles published in English, French, Spanish and German between January 1st, 2006 and November 20th, 2018 were included.

Search

This is the detailed search strategy used for PubMed: ("noacs"[All Fields] OR "noac"[All Fields] OR "non-vitamin k oral anticoagulants"[All Fields] OR "non-vka oral anticoagulant"[All Fields] OR "doacs"[All Fields] OR "doac"[All Fields] OR "direct oral anticoagulant"[All Fields] OR "direct oral anticoagulants"[All Fields] OR "factor xa inhibitor"[All Fields] OR "direct thrombin inhibitor"[All Fields] OR "dabigatran"[All Fields] OR "pradaxa"[All Fields] OR "rivaroxaban"[All Fields] OR "xarelto"[All Fields] OR "apixaban"[All Fields] OR "eliquis"[All Fields] OR "edoxaban"[All Fields] OR "lixiana"[All Fields] OR "savaysa"[All Fields]) AND ("ischemic stroke"[All Fields] OR "tia"[All Fields] OR "transient ischemic attack"[All Fields]) AND (("2006/01/01"[PDAT]: "2018/11/20"[PDAT]) AND "humans"[MeSH Terms] AND (German[lang] OR English[lang] OR French[lang] OR Spanish[lang]))).

Study selection

Citations were uploaded into the covidence online review tool. Their relevance was assessed against the predetermined inclusion and exclusion criteria by TRM and SF, who independently screened all titles and abstracts. Forward and backward reference searching complemented the database searches. Full-text manuscripts were obtained for all studies entering the review. Any uncertainties about including a specific manuscript in the review were resolved by consensus.
Data collection process
Data was extracted onto an Excel spreadsheet by SF and reviewed by TRM.

Data items
Data items included number of patients, age, sex, race, vascular risk factors, type of NOAC and dose, concomitant medication, clinical features of the AIE such as stroke severity, drug levels, renal function, coagulation parameters, imaging findings, stroke etiology, acute management and outcome parameters (functional outcome, mortality).

Risk of bias in individual and across studies
We compared data items, outcomes, design strengths and weaknesses across the studies. For each study, the risk of bias was thoroughly assessed at the study level using a modified National Heart, Lung, and Blood Institute (NHLBI) bias tool, and this information was incorporated when interpretation of data was given in the synthesis.

Summary measures
The principal summary measures were the clinical characteristics of patients using a NOAC in the setting of AIE.

Synthesis of results
If available and consistent throughout the studies, the pooled mean weighted corresponding to the sample size is presented. Data items given by median and interquartile range were converted assuming gaussian distribution as described earlier [10]. Until stated otherwise, the comparison to VKA patients is provided within each individual study.

Additional analyses
No additional analyses were performed.

Study selection
The database searches and citation tracking yielded 1309 hits, of which 1025 records were screened as potentially relevant after removing duplicates (Fig 1). Reasons for excluding relevant publications were mainly due to the lack of specific data items on individual patients. In total, 52 publications including 12247 patients met the inclusion criteria and were included in the analysis (1 substudy of a randomized interventional trial, 1 prospective non-randomized interventional trial, 1 nested case-control study, 28 non-randomized observational studies; 18 case series, 2 diagnostic studies, 1 substudy of an observational register).

Study characteristics
The extracted data of the included publications is shown in S1 Table.

Risk of bias within and across studies
We used 14 quality items to assess bias using a modified NHLBI bias tool [11]. We defined study quality as low when the sum of the positive quality items was less than six and moderate when it was between six and nine. Overall, the risk of bias was considerable across the studies. 20 studies had moderate quality, and 32 studies had low quality. Retrospective design, small sample size, publication bias, selective reporting and the slanted choice of a particular NOAC
therapy versus VKA therapy contributed to bias. The detailed bias assessment of each individual study using the modified NHLBI bias tool is available in the S2 Table.
Results

Risk factors and reasons for AIE while using a NOAC

In patients starting NOAC therapy, AIE were reported to occur more frequently during the first three months of treatment [12,13] with a declining AIE rate thereafter. Established risk factors such as previous AIE or an elevated CHA2DS2-VASc score were reported to predict AIE while using a NOAC [14–16]. Renal impairment, defined as estimated glomerular filtration rate of less than 60ml/min, was also reported to be a predictor of AIE while on NOAC therapy [17], which fits the borderline impaired pooled renal function parameters in our cohort. Kamal et al. reported an elevated mean body mass index (BMI) in NOAC failure [18]. This is in contrast to Arihiro et al. who found a reduced BMI patients with AIE in NOAC failure [19]. The mean weighted BMI in the pooled cohort was slightly elevated.

Severity and infarction size of AIE. Overall, AIS severity while on a NOAC measured by the National Institutes of Health Stroke Scale (NIHSS score) was mostly mild, and the outcome was favorable compared to AIS severity while on a VKA [13,15,20–27]. The mean weighted NIHSS score on admission in the pooled NOAC cohort was 4.6. In the biggest data set from the Get with the Guidelines Register, stroke severity while on a NOAC was equal to stroke severity while on a well-controlled dose of a VKA (NIHSS score 4), but stroke severity while on a NOAC was less severe when the international normalized ratio (INR) was not within the therapeutic range (NIHSS score 6) [28]. Opposing data was reported by Nakase et al., who found a higher NIHSS score in AIS while on a NOAC compared to VKA [29]. In patients qualifying for intravenous thrombolysis (IVT) or endovascular therapy (EVT), NIHSS score values were overall high, but roughly equal with NOAC and VKA pretreatment respectively [30–33].

The ischemic lesion size on magnetic resonance imaging (MRI) was reported to be significantly smaller while on a NOAC versus a VKA [23–25,29]. Also, in comparison to AIS while on acetylsalicylic acid, the size of the infarction on apixaban was smaller while the overall infarct rate was equal [34]. The distal middle cerebral artery territory was reported to be the most location of embolic strokes [18].

Dosing regimen. After propensity-score matching for baseline demographic parameters and co-morbidities, it was found that there was a significantly lower adherence rate than expected among the twice-daily NOAC users. The suboptimal adherence to any dosing regimen was reported to be associated with a 50% increased hazard ratio for AIS [35].

NOAC treatment was frequently found to be interrupted before an AIE [21,36]. Furthermore, subtherapeutic dosing was reported in a relevant proportion of patients as a possible explanation for NOAC failure [15,16,24,37,38]. For example, Sakamoto et al. found an inappropriately lowered dose in about 25% of patients in their cohort [15]. Nevertheless, AIE do occur despite NOAC drug levels being well within the therapeutic range [39].

Etiology. Overall, there are conflicting results regarding stroke subtypes in patients with AIE while on NOAC therapy. Some authors reported that cardioembolic sources, such as intracardiac thrombus or severe congestive heart failure, might present as a frequent reason for AIE under NOAC therapy [13,19–21]. On the other hand, other authors reported a predominantly non-cardioembolic etiology for AIS while on a NOAC, such as microvascular disease [15,40]. Other etiologies for AIS while on NOAC therapy include paraneoplastic coagulation disorders, arterio-arterial embolism [41] and polypharmacy [16].

Coagulation testing. Routine coagulation tests in patients undergoing NOAC therapy show strong variability and therefore cannot sufficiently predict current anticoagulant effect [42,43]. High plasma levels may remain elevated for more than 12 hours after last intake [43]. Despite this fact, specific coagulation tests are only performed in less than half of acute stroke patients in the emergency setting, even in experienced stroke centers [27,39].
Reperfusion therapies in the acute setting in patients with AIS under NOAC

IVT. In the Get With The Guidelines register, rates of IVT use were much lower in NOAC patients compared to subtherapeutic VKA patients in the (3.3% vs. 11.7%) [28]. Also, Purrucker et al. found NOAC treatment to be a significant barrier to IVT initiation and a cause of an overall lower rate of IVT usage (9/159 patients; 5.7%) in patients on NOAC therapy [44]. Suspected or proven NOAC treatment was reported to be the main reason for not administering IVT in more than half of all patients on their register. Also, an overall time delay to treatment of 35 minutes was reported in NOAC patients compared to VKA patients [30]. In the pooled cohort, the overall rate of IVT in most tertiary stroke centers was low (5.1%) and time from symptom onset to IVT was almost two and a half hours. Seiffge et al. could show, that more than half of patients on rivaroxaban could be candidates for IVT because of low plasma levels on admission [45].

Deciding for or against IVT. In the absence of specific coagulation testing, the time of the last NOAC dose prior to the AIS is of major importance in the decision to administer or withhold IVT, considering also the presence or absence of drug interactions as well as renal and hepatic function. Seiffge et al. reported that about half of their patients with an AIS had their last dose less than 12 hours before hospital admission, whereas the other half had their last dose between 12 and 24 hours before hospital admission [30]. Factor IIa activity assays are the standard of care in dabigatran users with an AIS in deciding for or against IVT. However, if not available, a thrombin time (TT) based protocol (<38 sec) might be a reasonable alternative [46]. Seiffge et al. showed that a specific factor Xa-activity assay is useful in patients treated with rivaroxaban with an AIE, and that the use of IVT in patients with low levels of factor Xa-activity might be safe. Despite using specific coagulation testing, a a fast door-to-needle time of 37 minutes was feasible [47].

Hemorrhagic complications after IVT. Two studies found no increase in acute-phase hemorrhagic transformation compared to VKA [15,48]. In the largest register dataset available, patients with NOAC pretreatment had the lowest unadjusted rates of life-threatening or serious systemic hemorrhage (0.4%) and of any other IVT complication (6.8%) compared to patients with antiplatelet, VKA or no medical pretreatment. However, data on coagulation parameters, the timing of the last NOAC intake, and whether nonspecific reversal strategies may have been applied were not available [49].

Olivera et al. reported ICH in two of seven patients taking a NOAC and receiving IVT. However, the definition of ICH was not clear [14]. Chen et al. reported severe bleeding events in 2/19 patients receiving IVT in patients taking rivaroxaban with both events occurring in patients with last drug intake <48h before IVT treatment [50]. In contrast, Seiffge et al. found a similar rate of symptomatic ICH using the National Institute of Neurological Disorders and Stroke (NINDS) or European Cooperative Acute Stroke Study II (ECASS-II) definition (sICH) in NOAC patients receiving IVT [30,51,52] and no sICH when the selection of therapy was guided by plasma levels in patients taking rivaroxaban [47]. Suzuki et al. reported no sICH at 24 hours in 71 patients receiving IVT with the study being limited by recall bias and reduced IVT dose [53].

Idarucizumab. In the biggest case series including 55 patients, IVT after dabigatran reversal was feasible with a symptom onset to needle time of 175 minutes [33]. Furthermore, its use was effective with a mean clinical improvement seen in 82% of the patients (6.3 points difference in NIHSS) and a follow-up mRS <2 in 56% of patients. The rate of sICH (3/55, 5.5%) was within the expected range. Other complications included one fatal thrombotic adverse
occurring five days after the Idarucizumab/IVT infusion [54]. However, most authors reported favourable outcome of this approach [55–57].

**Endovascular therapy (EVT).** A target large vessel occlusion was more often observed when NOAC dose was incorrectly low or compliance inadequate [58]. Seiffge et al. reported EVT without IVT in patients with high rivaroxaban plasma levels to be safe and feasible [30,47]. Several authors reported EVT to be safe and feasible with a similar rate of sICH as compared to patients without anticoagulation [59–63].

**Outcome.** Similar outcomes between AIE on NOAC or on VKA treatment were found [24]. This was also true in patients receiving IVT [30] and EVT [14,59]. Overall, in-hospital mortality was highest in patients not receiving antithrombotic treatment prior to the AIS (9.3%), followed by subtherapeutic warfarin (8.8%), antiplatelet treatment only (8.1%), therapeutic warfarin (6.4%), and NOAC (6.3%) [28].

**Management.** There are no randomized trials on the therapeutic management after AIE on NOAC. Following the AIE, switching temporarily to low molecular weight heparin was preferred by some authors [14], whereas most authors preferred switching to another NOAC with a different mechanism of action [40] for long-term prophylaxis. However, sometimes restarting the same NOAC was favored—possibly due to the good outcome of AIE on dabigatran and the possibility of antagonizing its effect by idarucizumab [33,54,64]. Also, a change of VKA was reported [14].

**Synthesis of results**

The pooled data is shown in Table 1. Additionally, in S3 Table we provide the pooled data considering only studies of at least moderate quality, although there were no relevant differences compared to the data of all included studies.

**Additional analysis**

No additional analysis was performed.

**Discussion**

**Epidemiology**

It was expected that about 1% of AIS patients will be on NOAC treatment in the future [65]. With an estimated AIE rate of 1–2% per year in patients taking a NOAC and the increasing number of indications for NOAC use, this rate is likely to increase significantly [66] reaching 6% in 2017 in our tertiary stroke center.

**Risk factors and reasons for AIE under NOAC**

Information on stroke subtype distribution according to validated classifications such as the Trial of Org 10172 in Acute Stroke Treatment (TOAST) or ASCOD in AIE under NOAC is currently not available [67,68].

Apart from the classical etiologies, there are several potential reasons for an AIE while taking a NOAC, including non-adherence to medication, under-dosage and potential treatment failure of NOAC with thrombus formation despite treatment.

The finding that classical vascular risk factors are associated with AIE under NOAC suggests that large artery disease or small vessel disease may represent a cause of AIE in a relevant percentage of patients [69]. However, incorporation of biomarkers associated with cardioembolic etiology (Cardiac troponin I, N-terminal pro-B-type natriuretic peptide, and D-dimer) enhanced risk assessment for subsequent ischemic events [70]. Surprisingly, the finding that
Table 1. Pooled characteristics of patients suffering acute cerebral ischemic events while taking non-vitamin K antagonist oral anticoagulants (N = 12247).

| Characteristic                      | item positive | item available | %   | Weighted mean |
|-------------------------------------|---------------|----------------|-----|---------------|
| Female sex                          | 5594          | 10898          | 51.3|                |
| Age (years)                         | 10989         |                |     | 78.6          |
| BMI (kg/m²)                         | 750           |                |     | 26.3          |
| **Medical history**                 |               |                |     |               |
| Atrial fibrillation                 | 11036         | 11301          | 97.7|                |
| Hypertension                        | 8614          | 10450          | 82.4|                |
| Dyslipidemia/hyperlipidemia         | 4984          | 9721           | 51.3|                |
| Previous ischemic stroke or TIA    | 4465          | 10191          | 43.8|                |
| Coronary heart disease or myocardial infarction | 3438 | 10040 | 34.2 | |
| Diabetes mellitus                   | 3456          | 10436          | 33.1|                |
| Heart failure                       | 2013          | 9616           | 20.9|                |
| Smoker                              | 745           | 9298           | 8.0 |                |
| Peripheral vascular disease         | 575           | 8900           | 6.5 |                |
| Carotid stenosis                    | 415           | 8859           | 4.7 |                |
| Prosthetic heart valve              | 142           | 8768           | 1.6 |                |
| **NOAC**                            |               |                |     |               |
| Rivaroxaban (total)                 | 1626          | 3092           | 52.6|                |
| Dabigatran (total)                  | 1162          | 3092           | 37.6|                |
| Apixaban (total)                    | 299           | 3092           | 9.7 |                |
| Edoxaban (total)                    | 5             | 3092           | 0.2 |                |
| Twice daily                         | 635           | 1150           | 55.2|                |
| Once daily                          | 500           | 1150           | 43.5|                |
| **Medication**                      |               |                |     |               |
| Antihypertensive                    | 7170          | 9190           | 78.0|                |
| Cholesterol lowering drug           | 5866          | 9587           | 61.2|                |
| Diabetes medication                 | 2054          | 8859           | 23.2|                |
| Concomitant antiplatelet            | 333           | 1668           | 20.0|                |
| **Laboratory**                      |               |                |     |               |
| Serum creatinine (mg/dl)            | 833           |                | 0.95|                |
| Renal clearance (ml/min)            | 897           |                | 63.5|                |
| aPTT (sec)                          | 650           |                | 34.5|                |
| INR                                 | 9756          |                | 1.2 |                |
| Blood glucose (mg/dl)               | 742           |                | 124.2|               |
| D-Dimer (ng/ml)                     | 128           |                | 964.1|               |
| BNP (pg/ml)                         | 128           |                | 198.4|               |
| **Clinical features**               |               |                |     |               |
| Stroke severity (NIHSS score)       | 10291         |                | 4.6 |                |
| **Treatment**                       |               |                |     |               |
| Any IVT                             | 598           | 9196           | 6.5 |                |
| Onset of symptoms to IVT (min)      | 402           |                | 141.9|               |
| Time since last drug intake to IVT (h) | 276 | | 10.2 | |

BMI: body mass index, aPTT: activated Partial Thromboplastin Time, INR: international normalized ratio, BNP: brain natriuretic peptide, NIHSS: National Institute of Health Stroke Severity, IVT: intravenous thrombolysis.

[https://doi.org/10.1371/journal.pone.0213379.t001](https://doi.org/10.1371/journal.pone.0213379.t001)

previous AIS predicts treatment failure is in contrast to a subgroup analysis of the ROCKE-T-AF trial [71]. Future research should address the question whether impaired renal function
is an independent predictor of AIE in patients taking NOAC or only if inadequate dosing is prescribed. Importantly, it was shown, that excellent renal function was a risk factor of AIE, at least in patients receiving Edoxaban [72].

Recurrent AIE is reported to occur more frequently in the first three months after NOAC therapy initiation, which behooves caregivers and patients to be especially attentive to the signs of an AIE. The elevated risk in the first weeks after the event at the same time of NOAC initiation might explain this observation. However, it might also be possible that the increased incidence in the first three months may be because NOACs may induce the mobilization of preexisting thrombi. Comparison of NOAC initiation for primary and secondary prophylaxis could clarify this phenomenon. Insufficient drug levels due to varying drug interactions have been analyzed [73], but their relevance in the real-world setting remains unclear.

Furthermore, early termination in up to one of three NOAC patients within the first year of treatment has been reported [74,75]. In this setting, mild cognitive dysfunction was not a risk factor for non-adherence [76].

Severity and infarction size of AIE
The severity of an AIS while on a NOAC seems to be at least equal compared to VKA pretreatment. This finding is confirmed by another study that showed an equally reduced frequency of severe strokes in patients on therapeutic doses of a VKA as well as patients on NOAC therapy [77]. There is insufficient data on AIS size, although preliminary data, which showed smaller infarct volumes on MRI, was reassuring [25].

Dosing regimen
Once daily dosing seems to be associated with a slightly better adherence [78]; although its effect in clinical practice is unclear because worse pharmacokinetics could easily balance this benefit [79]. Because body weight and renal function might be altered in the acute event setting, NOAC doses should be reviewed after about three weeks [38]. Treatment discontinuation in about a quarter of patients at one year demands care models increasing the delivery of continuous therapy [80].

Laboratory parameters
Abnormal routine coagulation tests may provide a hint that a patient presenting with an AIE might take a NOAC, but they do not reflect the actual coagulation status. Specific tests for the activity of a particular NOAC should be used routinely, because they aid in the decision to administer or withhold IVT. Prospective studies with consistent data are warranted to define reliable recommended cut-off values for each NOAC.

Reperfusion therapies in the acute setting in patients with AIS under NOAC
IVT. There are no randomized trials concerning IVT in the setting of an AIS under a NOAC. Seiffge et al. estimated that IVT could be used in more than half of patients with prior rivaroxaban treatment with about 28% of patients denied by current guidelines [30,45,81]. Recent analyses concluded that IVT is probably effective and safe in select AIS patients undergoing NOAC treatment [81–84]. However, optimal patient selection is dependent on coagulation parameters that have not yet been sufficiently evaluated, and the variable selection criteria used in available studies do not allow for a consensus [39,42,85,86]. Prospective, randomized
studies are crucial for the creation of valid guidelines for this situation comparable to the INR cutoff in VKA patients.

**EVT.** EVT also seems to be safe and effective in large vessel occlusion (LVO) in patients undergoing NOAC therapy, but further trials are needed to confirm general safety [60,87]. Either on its own or in combination with, recanalization strategies are available for about one out of three patients with an AIS undergoing therapy with a NOAC [47].

**NOAC reversal agents.** Initial reports on successful and safe IVT after idarucizumab administration are promising, but limited experience does not allow for a final statement on the safety of IVT after antagonization [33,84]. Additionally, it is not clear whether idarucizumab/IVT should be administered in every dabigatran patient with an AIS or only if direct EVT is not possible. No data is presently available for the recently approved reversal agent for factor Xa inhibitors, andexanet alfa.

**ICH.** The incidence of ICH after an AIS with or without IVT/EVT seems to be low, but systematic prospective trials are lacking. Furthermore, heterogeneous definitions of a symptomatic ICH impair the comparability of study results.

**Management.** Since guidelines on the management of an AIE under NOAC therapy are lacking, and the underlying etiology is heterogeneous, it seems to be most important to search for potentially treatable sources of stroke, such as symptomatic atherosclerotic stenosis, paraneoplastic syndrome, vasculitis or endocarditis. Moreover, a measurement of NOAC activity on admission may help to identify instances of compliance-related AIE and to guide individualized dosing of NOACs in the future.

When none of the listed etiologies are found, it is controversial, but many clinicians switch to another NOAC substance [88].

**Summary of evidence**

AIE in patients using a NOAC are becoming a more frequent event. Contributing risk factors as well as the etiology remain poorly understood. Stroke severity seems to be favorable or at least equal to an AIS that occurs while on a VKA. Standardized management protocols for diagnostic work-up and management are necessary to provide optimal and rapid stroke care. IVT and EVT seem to be safe and effective, but patient selection for these therapies is challenging.

**Limitations**

Our analysis has several limitations that limit the generalization of findings. Those include the overall low quality of published data, statistical pooling procedures, incomplete retrieval of identified research, reporting bias, and the small number of reports of patients suffering from an AIE while using Apixaban and Edoxaban. Furthermore, we only report characteristics of patients suffering AIE while taking NOAC, but we had no information on patients on NOAC not suffering AIE which limits the explanatory power of the findings.

**Conclusions**

There is an unmet need for prospective trials on the diagnostic workup and treatment of an AIE under NOAC therapy. High volume registers of patients suffering from an AIE while undergoing NOAC therapy are already being created and will hopefully soon contribute to the management of AIE under NOAC therapy. (RASUNOA prime, ClinicalTrials: NCT02533960; NOACISP; ClinicalTrials: NCT02353585, ARAMIS Register, ClinicalTrials: NCT02478177).

**Studies included.** [12–16,18–24,26–29,31,34,37,40–42,44,46,47,49,54–56,58,59,64,77,78,83,89–101].
Supporting information

S1 Table. Extracted data of included studies. Extracted items are shown.
(XLSX)

S2 Table. Bias assessment tool. For each study, the risk of bias was thoroughly assessed at the
study level using a modified National Heart, Lung, and Blood Institute (NHLBI) bias tool rec-
commended for non-randomized observational studies.
(XLSX)

S3 Table. Pooled characteristics of patients suffering acute cerebral ischemic events
according to study quality. Data is presented of all included patients suffering acute cerebral
ischemic events while taking non-vitamin K oral anticoagulants (N = 12247) and only consider-
ing studies of at least moderate quality (n = 10840).
(DOCX)

S4 Table. Prisma checklist. Checklist of systematic reviews according to the PRISMA guide-
lines.
(DOC)

Author Contributions

Conceptualization: Thomas Raphael Meinel, Marcel Arnold, Simon Jung.

Data curation: Thomas Raphael Meinel, Sébastien Frey.

Formal analysis: Thomas Raphael Meinel.

Investigation: Thomas Raphael Meinel, Sébastien Frey.

Methodology: Thomas Raphael Meinel, Johannes Kaesmacher, Mirjam Rachel Heldner,
Simon Jung.

Project administration: Marcel Arnold.

Resources: Urs Fischer.

Supervision: Marcel Arnold, Urs Fischer, Johannes Kaesmacher, Simon Jung.

Writing – original draft: Thomas Raphael Meinel, Sébastien Frey.

Writing – review & editing: Thomas Raphael Meinel, Marcel Arnold, Sarah Kendrout, Urs
Fischer, Johannes Kaesmacher, Mirjam Rachel Heldner, Simon Jung.

References

1. Endres M, Diener H, Behnke M, Röther J, Daniels W, Dichgans M, et al. S3-Leitlinie Sekundärprophy-
laxe ischämischer Schlaganfall und transitorische ischämische Attacke [Internet]. [cited 19 Oct 2017].
Available: https://www.dgn.org/images/red_leitlinien/LL_2014/PDFs_download/030-133_lang_S3_-
Sekundärprophylaxe_ischämischer_Schlaganfall_2015-02.pdf

2. You JJ, Singer DE, Howard PA, Lane DA, Eckman MH, Fang MC, et al. Antithrombotic Therapy for
Atrial Fibrillation. Chest. 2012; 141: e531S–e575 S. https://doi.org/10.1378/chest.11-2304 PMID:
22315271

3. Verma A, Cairns JA, Mitchell LB, Macle L, Stiell IG, Gladstone D, et al. 2014 focused update of the
Canadian Cardiovascular Society Guidelines for the management of atrial fibrillation. Can J Cardiol.
2014; 30: 1114–30. https://doi.org/10.1016/j.cjca.2014.08.001 PMID: 25262857

4. Kirchhof P, Benussi S, Kotecha D, Ahlsson A, Atar D, Casadei B, et al. 2016 ESC Guidelines for the
management of atrial fibrillation developed in collaboration with EACTS. Eur Heart J. 2016; 37. https://
doi.org/10.1093/eurheartj/ehw210 PMID: 27567408
5. Almutairi AR, Zhou L, Gellad WF, Lee JK, Slack MK, Martin JR, et al. Effectiveness and Safety of Non-Vitamin K Antagonist Oral Anticoagulants for Atrial Fibrillation and Venous Thromboembolism: A Systematic Review and Meta-Analyses. Clin Ther. 2017; 39: 1456–1478.e36. https://doi.org/10.1016/j.clinthera.2017.05.358 PMID: 28686828

6. Granger CB, Alexander JH, McMurray JJV, Lopes RD, Hylek EM, Hanna M, et al. Apixaban versus Warfarin in Patients with Atrial Fibrillation. N Engl J Med. 2011; 365: 981–992. https://doi.org/10.1056/NEJMoai107039 PMID: 21870978

7. Giugliano RP, Ruff CT, Braunwald E, Murphy SA, Wiviott SD, Halperin JL, et al. Edoxaban versus Warfarin in Patients with Atrial Fibrillation. N Engl J Med. 2013; 365: 983–2014. https://doi.org/10.1056/NEJMoai310907 PMID: 24251359

8. Patel MR, Mahaffey KW, Garg J, Pan G, Singer DE, Hacke W, et al. Rivaroxaban versus Warfarin in Nonvalvular Atrial Fibrillation. N Engl J Med. Massachusetts Medical Society; 2009; 361: 1139–1151. https://doi.org/10.1056/NEJMoa0905561 PMID: 19717844

9. Hozo SP, Djulbegovic B, Hozo I. Estimating the mean and variance from the median, range, and the size of a sample. BMC Med Res Methodol. 2005; 5: 13. https://doi.org/10.1186/1471-2288-5-13 PMID: 15840177

11. NHLBI. Quality Assessment Tool for Observational Cohort and Cross-Sectional Studies [Internet]. [cited 19 Sep 2018]. Available: https://www.nhlbi.nih.gov/health-topics/study-quality-assessment-tools

12. Defelipe-Mimbrera A, Cánovas AA, Guiller M, Matute C, Sainz De La Maza S, Cruz A, et al. Dabigatran in Secondary Stroke Prevention: Clinical Experience with 106 Patients. BioMed Research International. 2014. p. 6. https://doi.org/10.1155/2014/567026 PMID: 25133166

15. Sakamoto Y, Okubo S, Nito C, Suda S, Matsumoto N, Abe A, et al. The relationship between stroke severity and prior direct oral anticoagulant therapy in patients with acute ischaemic stroke and non-valvular atrial fibrillation. Eur J Neurol. 2017; 24: 1399–1406. https://doi.org/10.1111/ejne.13405 PMID: 28799181

16. Antoniou T, Macdonald EM, Yao Z, Hollands S, Gomes T, Tadrous M, et al. Association between statin use and ischemic stroke or major hemorrhage in patients taking dabigatran for atrial fibrillation. CMAJ. 2017; 189: E4–E10. https://doi.org/10.1503/cmaj.160303 PMID: 28246253

22. Sano H, Deguchi I, Fukuoka T, Nagamine Y, Mizuno S, Horiiuchi Y.-S., et al. Ischemic stroke in patients having NOACs show better prognosis than in ones having warfarin. Clin Neurol. 2016; 56: S342.
23. Shibata Y, Nakamura A, Yasaka M, Kuwashiro T, Gotoh S, Takaguchi G, et al. Neurological severity and infarct size in patients with acute ischemic stroke during DOAC treatment for nonvalvular atrial fibrillation. Stroke. 2017; 48: Supplement 1.

24. Kaniy Y, Oguro H, Tahara N, Matsuda H, Takayoshi H, Mitaki S, et al. Analysis of Recurrent Stroke Volume and Prognosis between Warfarin and Four Non–Vitamin K Antagonist Oral Anticoagulants’ Administration for Secondary Prevention of Stroke. J Stroke Cerebrovasc Dis. 2018; 27: 338–345. https://doi.org/10.1016/j.jstrokecerebrovasdis.2017.09.007 PMID: 29033229

25. Oguro H, Mizuhara R, Abe S, Takayoshi H, Mitaki S, Onoda K, et al. Analysis of Recurrent Stroke Volume between VKA (Vitamin K Antagonist) and Three NOACs (Non-Vitamin K Antagonist Oral Anticoagulants) under Oral Anticoagulant Therapy. Int J Pharm Sci Res. 2016; 3. https://doi.org/10.15344/2394-1502/2016/116 International

26. Piccardi B, Fratangelo R, Lamassa M, Nencini P, Pescini F. Ischemic stroke in patients treated with anticoagulants: Retrospective analysis from hospital-based register. Eur Stroke J. B. Piccardi, Careggi University Hospital, Stroke Unit, Florence, Italy; 2018; 3: 469. https://doi.org/10.1177/239687318770127 https://sfx.metabib.ch/sfx_locater?sid=EMBASE&issn=23968881&id=doi:10.1177%2F239687318770127&tittle=Ischemic+stroke+in+patients+treated+with+anticoagulants%3A+Retrospective+analysis+from+hospital-based+register&stitle=Eur.+Stroke+J.&title=European+Stroke+Journal&volume=3&issue=1&page=&aulast=Piccardi&aufirst=B.&auinit=B.&aufull=Piccardi+B.&code=469&date=2018&auinit1=B&auinit2=B.

27. Valente M, Leung S, Wu P, Dewey H, Choi P. Acute ischemic stroke and TIA whilst on anticoagulants—clinical characteristics and functional outcomes in the era of direct oral anticoagulants. Int J Stroke. M. Valente, Department of Neuroscience, Eastern Health, Box Hill, Australia; 2018; 13: 12. https://doi.org/10.1177/1747493018778666 https://sfx.metabib.ch/sfx_locater?sid=EMBASE&issn=17474949&id=doi:10.1177%2F1747493018778666&tittle=Acute+ischaemic+stroke+and+TIA+whilst+on+anticoagulants—clinical+characteristics+and+functional+outcomes+in+the+era+of+direct+oral+anticoagulants&stitle=Int.+J.+Stroke&title=International+Journal+of+Stroke&volume=13&issue=1&page=&aulast=Valente&aufirst=Michael&auinit=M.&aufull=Valente+M.&code=469&date=2018&auinit1=M&auinit2=M.

28. Xian Y, O’Brien EC, Liang L, Xu H, Schwamm LH, Fonarow GC, et al. Association of Preceding Antithrombotic Treatment With Acute Ischemic Stroke Severity and In-Hospital Outcomes Among Patients With Atrial Fibrillation. JAMA. 2017; 317: 1057. https://doi.org/10.1001/jama.2017.1371 PMID: 28291892

29. Nakase T, Moroi J, Ishikawa T. Difference of Clinical Condition of Ischemic Stroke between Warfarin and Direct Oral Anticoagulants (P6.285). Neurology. 2017; 88: Supplement P6.285.

30. Seifge DJ, Hooff R-J, Nolte CH, Bejot Y, Turc G, Ikenberg B, et al. Recanalization therapies in acute ischemic stroke patients: impact of prior treatment with novel oral anticoagulants on bleeding complications and outcome. Circulation. 2015; 132: 1261–1269. https://doi.org/10.1161/CIRCULATIONAHA.115.015484 PMID: 26232277

31. Kimura S, Ogata T, Fukae J, Okawa M, Higashi T, Iwaasa M, et al. Revascularization for acute ischemic stroke is safe for rivaroxaban users. J Stroke Cerebrovasc Dis. Elsevier Ltd; 2014; 23: e427–e431. https://doi.org/10.1016/j.jstrokecerebrovasdis.2014.05.015 PMID: 25149204

32. Pikija S, Sztiriha LK, Sebastian Mutzenbach J, Golaszewski SM, Sellner J. Idarucizumab in Dabigatran-Treated Patients with Acute Ischemic Stroke Receiving Alteplase: A Systematic Review of the Available Evidence. CNS Drugs. 2017; 31. https://doi.org/10.1007/s40263-017-0460-x PMID: 28808918

33. Giannandrea D, Caponi C, Mengoni A, Romoli M, Marando C, Gallina A, Marsili E, Sacchini E, Mastrolata S, Padiglioni C, Mazzoli T, Cenciarelli SRS. Intravenous thrombolysis in stroke after dabigatran reversal with idarucizumab: case series and systematic review. J Neurol Neurosurg Psychiatry. 2018; July: 1–5. https://doi.org/10.1136/jnnp-2018–318658

34. O’Donnell MJ, Eikelboom JW, Yusuf S, Diener HC, Hart RG, Smith EE, et al. Effect of apixaban on brain infarction and microbleeds: AVERROES-MRI assessment study. Am Heart J. Elsevier B.V.; 2016; 178: 145–150. https://doi.org/10.1016/j.ahj.2016.03.019 PMID: 27502862

35. Alberts MJ, Peacock WF, Fields LE, Bunz TJ, Nguyen E, Milentijevic D, et al. Association between once- and twice-daily direct oral anticoagulant adherence in nonvalvular atrial fibrillation patients and rates of ischemic stroke. Int J Cardiol. 2016; 215: 11–13. https://doi.org/10.1016/j.ijcard.2016.03.212 PMID: 27104919

36. Cavallari I, Ruff CT, Nordio F, Deenadayalu N, Shi M, Lanz H, et al. Clinical events after interruption of anticoagulation in patients with atrial fibrillation: An analysis from the ENGAGE AF-TIMI 48 trial. Int J Cardiol. Elsevier B.V.; 2018; 257: 102–107. https://doi.org/10.1016/j.ijcard.2018.01.065 PMID: 29395361
37. Kato Y, Hayashi T, Tanahashi N, Takao M. The Dose of Direct Oral Anticoagulants and Stroke Severity in Patients with Acute Ischemic Stroke and Nonvalvular Atrial Fibrillation. J Stroke Cerebrovasc Dis. Elsevier Inc.; 2018; 27: 1490–1496. https://doi.org/10.1016/j.jstrokecerebrovasdis.2017.12.038 PMID: 29398536

38. Shinoda N, Mori M, Tamura S, Korosue K, Kose S, Kohmura E. Risk of Recurrent Ischemic Stroke with Unintended Low-Dose Oral Anticoagulant Therapy and Optimal Timing of Review. J Stroke Cerebrovasc Dis. Elsevier Inc.; 2018; 27: 1546–1551. https://doi.org/10.1016/j.jstrokecerebrovasdis.2018.01.002 PMID: 29395644

39. Purrucker JC, Haas K, Rizos T, Khan S, Poli S, Kraft P, et al. Coagulation Testing in Acute Ischemic Stroke Patients Taking Non-Vitamin K Antagonist Oral Anticoagulants. Stroke. 2017; 48: 152–158. https://doi.org/10.1161/STROKEAHA.116.014963 PMID: 27899756

40. Cappellari M, Bovi P. Continuation of direct oral anticoagulants in the acute phase of ischemic stroke. A case series. J Thromb Thrombolysis. Springer US; 2017; 43: 248–251. https://doi.org/10.1007/s11239-016-1430-8 PMID: 27699550

41. Kim BJ, Kang HG, Lee DH, Kang D-W, Kim JS, Kwon SU. Ischemic Stroke on Optimal Anticoagulation with Novel-Oral Anticoagulants Compared with Warfarin. Int J Stroke. 2015; 10: E68–E68. https://doi.org/10.1111/ijs.12587 PMID: 26202718

42. Kepplinger J, Prakapenka A, Barlinn K, Siegert G, Gehrisc H, Zerna C, et al. Standardized use of novel oral anticoagulants plasma level thresholds in a new thrombolysis decision making protocol. J Thromb Thrombolysis. 2015; 41. https://doi.org/10.1007/s11239-015-1229-z PMID: 26001908

43. Seifig D, Kägi G, Zeddè M, Bejoï Y, Turc G, Michel P, et al. Rivaroxaban plasma levels in patients with acute ischemic stroke and intracerebral hemorrhage. Eur Stroke J. 2017; 2: 99–100. https://doi.org/10.1177/2396987317705242

44. Purrucker JC, Haas K, Rizos T, Khan S, Poli S, Kraft P, et al. Coagulation testing in acute ischemic stroke patients taking non-Vitamin K antagonist oral anticoagulants. Stroke. 2017; 48: 152–158. https://doi.org/10.1161/STROKEAHA.116.014963 PMID: 27899756

45. Seifig DJ, Kägi G, Michel P, Fischer U, Béjot Y, Wegener S, et al. Rivaroxaban plasma levels in acute ischemic stroke and intracerebral hemorrhage. Ann Neurol. 2018; 83: 451–459. https://doi.org/10.1002/ana.25165 PMID: 29394504

46. Kate M, Szkotak A, Witt A, Shuaib A, Butcher K. Proposed approach to thrombolysis in dabigatran-treated patients presenting with ischemic stroke. J Stroke Cerebrovasc Dis. Elsevier Ltd; 2014; 23: 1351–1355. https://doi.org/10.1016/j.jstrokecerebrovasdis.2013.11.013 PMID: 24406026

47. Seifig DJ, Traenka C, Polymeris AA, Thilemann S, Wagner B, Hert L, et al. Intravenous Thrombolysis in Patients with Stroke Taking Rivaroxaban Using Drug Specific Plasma Levels: Experience with a Standard Operation Procedure in Clinical Practice. J Stroke. 2017; 19: 1–10. https://doi.org/10.5853/jos.2016.00024

48. Purrucker JC, Haas K, Wolf M, Rizos T, Khan S, Kraft P, et al. Haemorrhagic Transformation after Ischaemic Stroke in Patients Taking Non-vitamin K Antagonist Oral Anticoagulants. J Stroke. 2017; 19: 67–76. https://doi.org/10.5853/jos.2016.00052 PMID: 28178406

49. Xian Y, Federspiel JJ, Hernandez AF, Laskowitz DT, Schwamm LH, Bhatt DL, et al. Use of Intravenous Recombinant Tissue Plasminogen Activator in Patients With Acute Ischemic Stroke Who Take Non–Vitamin K Antagonist Oral Anticoagulants Before StrokeClinical Perspective. Circulation. 2017; 135: 1024–1035. https://doi.org/10.1161/CIRCULATIONAHA.116.023940 PMID: 28119380

50. Chen ST, Hellkamp AS, Becker RC, Berkowitz SD, Breithardt G, Fox KAA, et al. Outcome of Patients Receiving Thrombolytic Therapy While on Rivaroxaban for Nonvalvular Atrial Fibrillation (From Rivaroxaban Once Daily Oral Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atr). Am J Cardiol. Elsevier Inc.; 2017; 120: 1837–1840. https://doi.org/10.1016/j.amjcard.2017.07.095 PMID: 28886856

51. Hacke W, Kaste M, Fieschi C, von Kummer R, Davalos A, Meier D, et al. Randomised double-blind placebo-controlled trial of thrombolytic therapy with intravenous alteplase in acute ischaemic stroke (ECASS II). Second European-Australasian Acute Stroke Study Investigators. Lancet. Elsevier; 1998; 352: 1245–51. https://doi.org/10.1016/S0140-6736(98)08020-9 PMID: 9788453

52. National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. Tissue Plasminogen Activator for Acute Ischemic Stroke. N Engl J Med. 1995; 333: 1581–1588. https://doi.org/10.1056/NEJM199512143332401 PMID: 7477192

53. Suzuki K, Aoki J, Sakamoto Y, Abe A, Suda S, Okubo S, et al. Low risk of ICH after reperfusion therapy in acute stroke patients treated with direct oral anti-coagulant. J Neurol Sci. Elsevier B.V.; 2017; 379: 207–211. https://doi.org/10.1016/j.jns.2017.06.004 PMID: 28716241

54. Kermer P, Eschenfelder CC, Diener H-C, Grond M, Abdalla Y, Althaus K, et al. Antagonizing dabigatran by idarucizumab in cases of ischemic stroke or intracranial hemorrhage in Germany–A national
case collection. Int J Stroke. 2017; 12: 1747. https://doi.org/10.1177/1747493017701944 PMID: 28494694

55. Pikija S, Sziroha LK, Sebastian Mutzenbach J, Golaszewski SM, Sellner J. Idarucizumab in Dabigatran-Treated Patients with Acute Ischemic Stroke Receiving Alteplase: A Systematic Review of the Available Evidence. CNS Drugs. 2017; 31: 747–757. https://doi.org/10.1007/s40263-017-0460-x PMID: 28808918

56. Šaňáık D, Jakubiček S, Černík D, Herzig R, Kunáš Z, Mikulík R, et al. Intravenous Thrombolysis in Patients with Acute Ischemic Stroke after a Reversal of Dabigatran Anticoagulation with Idarucizumab: A Real-World Clinical Experience. J Stroke Cerebrovasc Dis. 2018; 27: 2479–2483. https://doi.org/10.1016/j.jstrokecerebrovasdis.2018.05.004 PMID: 29807757

57. Frol S, Pretnar Oblak J. Safe and very effective intravenous thrombolysis after idarucizumab application in stroke patients receiving dabigatran therapy: A case series. Int J Stroke. S. Frol, University Clinical Centre Ljubljana, Department of vascular neurology, Ljubljana, Slovenia; 2018; 13: 218–219. https://doi.org/10.1117/1747493018789543 LK - http://sfx.metabib.ch/sfx_locater?sid=EMBASE&issn=17474949&d=10.1177%2F1747493018789543&title=Safe+and+very+effective+intravenous+thrombolysis+after+idarucizumab+application+in+stroke+patients+receiving+dabigatran+therapy%3A+A+case+series&title=Int.+J.+Stroke&volume=13&issue=2&page=218&epage=219&aulast=Frol&aufirst=S.&auinit= &sisbn= &isbn= &pages=218-219 &date=2018 &auinit1=S&auinit2=G

58. Woo H, Han M. Patterns of stroke recurrence in ischemic stroke patients taking non-vitamin K antagonist oral anticoagulation. Cerebrovasc Dis. H.G. Woo, Soonchunhyang University Cheonan Hospital, South Korea; 2018; 46: 23. https://doi.org/10.1159/000493155 LK - http://sfx.metabib.ch/sfx_locater?sid=EMBASE&issn=14219786&d=10.1177%2F000493155&title=Patterns+of+stroke+recurrence+in+ischemic+stroke+patients+taking+non-vitamin+K+antagonist+oral+anticoagulation+&title=Cerebrovascular+Diseases&volume=46&issue=&page=23&epage=&aulast=Woo&aufirst=H.&auinit=H.G.&coden=&isbn=&pages=23–&date=2018 &auinit1=H&auinit2=M

59. Rebello LC, Haussen DC, Belagaje S, Anderson A, Frankel M, Nogueira RG. Endovascular treatment for acute ischemic stroke in the setting of anticoagulation. Stroke. 2015; 46: 3536–3539. https://doi.org/10.1161/STROKEAHA.115.011285 PMID: 26470775

60. Zapata-Wainberg G, Ximénez-Carrillo A, Trillo S, Fuentes B, Cruz-Culebras A, Aguirre C, et al. Mechanical thrombectomy in orally anticoagulated patients with acute ischemic stroke. J Neurointerv Surg. 2018; 10: 834–838. https://doi.org/10.1136/neurintsurg-2017-013504 PMID: 29275325

61. Krajčíková D, Vysata O, Čabeková P, Halúsková S, Vášář M, Vlková E, et al. Safety and efficacy of mechanical thrombectomy with stent-retrievers in anticoagulated patients with anterior circulation stroke. Clin Radial. 2018; 74: 165.e11-165.e16. https://doi.org/10.1007/s00270-018-1902-7 PMID: 29450625

62. D. Č, D. Š., P. D, M. K, F. C, J. Z, et al. Mechanical Thrombectomy in Patients with Acute Ischemic Stroke on Anticoagulation Therapy. Cardiovasc Intervent Radiol. 2018; 41: 706–711. https://doi.org/10.1007/s00270-018-1902-7 PMID: 29450625

63. Kurowski D, Jonczak K, Shah Q, Yaghi S, Marshall RS, Ahmad H, et al. Safety of Endovascular Intervention for Stroke on Therapeutic Anticoagulation: Multicenter Cohort Study and Meta-Analysis. J Stroke Cerebrovasc Dis. Elsevier Inc.; 2017; 26: 1104–1109. https://doi.org/10.1016/j.jstrokecerebrovasdis.2016.12.027 PMID: 28110890

64. Nedkova Hristova V, De Felipe Mimbrela A, Escribano-Paredes B, Martinez Poles J, Garcia Madrona S, Perez Torre R, et al. Clinical characteristics of ischemic stroke in patients treated previously with direct oral anticoagulants. Eur J Neurol. V. Nedkova Hristova, Neurology, Hospital Universitario Ramón y Cajal, Madrid, Spain; 2018; 25: 389.

65. Pfeilslchter W, Farahmand D, Niemann D, Ikenberg B, Hohmann C, Abruscato M, et al. Estimating the Quantitative Demand of NOAC Antidote Doses on Stroke Units. Cerebrovasc Dis. 2016; 42: 415–420. https://doi.org/10.1159/000447952 PMID: 27438461

66. Pollack C V. Evidence Supporting Idarucizumab for the Reversal of Dabigatran. Am J Med. Elsevier; 2016; 129: S73–S79. https://doi.org/10.1016/j.amjmed.2016.06.008 PMID: 27568285

67. Adams H., Bendixen B., Kappelle L., Biller J, Love B., Gordon D., et al. Classification of Subtype of Acute Ischemic Stroke. Stroke. 1993; 23: 35–41. https://doi.org/10.1161/01.STR.24.1.35

68. Amarencp C, Bogousslavsky J, Caplan LR, Donnan GA, Wolf ME, Hennerici MG. The ASCOD phenotyping of ischemic stroke (Updated ASCO Phenotyping). Cerebrovasc Dis. 2013; 36: 1–5. https://doi.org/10.1055/s-0035-152050 PMID: 23899749

69. Elvira-Ruiz G, Caro-Martinez C, Andreu-Cayuelas J, Flores-Blanco P, H A-I, Gomez-Molina M, et al. Comparison of thrombembolic and bleeding risk scores in direct oral anticoagulant naive patients with non-valvular atrial fibrillation. Eur Heart J. G. Elvira-Ruiz, University Hospital Virgen De La
Arrixaca, Murcia, Spain; 2017;38: 967. https://doi.org/10.1093/eurheartj/ehx502.P4575

70. Ruff CT, Gligiiano RP, Braunwald E, Murphy SA, Brown K, Jarolim P, et al. Cardiovascular biomarker score and clinical outcomes in patients with atrial fibrillation: A subanalysis of the ENGAGE AF-TIMI 48 randomized clinical trial. JAMA Cardiol. 2016; 1: 999–1006. https://doi.org/10.1001/jamacardio.2016.3311 PMID: 27706467

71. Hankey GJ, Patel MR, Stevens SR, Becker RC, Breithardt G, Carolei A, et al. Rivaroxaban compared with warfarin in patients with atrial fibrillation and previous stroke or transient ischemic attack: A subgroup analysis of ROCKET AF. Lancet Neurol. 2012; 11: 315–322. https://doi.org/10.1016/S1474-4422(12)70042-X PMID: 22402056

72. Yu HT, Yang P-S, Joung B. Impact of Renal Function on Outcomes With Edoxaban in Real-World Patients With Atrial Fibrillation. Stroke. 2018; 49: 2421–2429. https://doi.org/10.1161/STROKEAHA.118.003929 PMID: 30355093

73. Xiong Q, Lau YC, Lip GYH. Pharmacodynamic profile and drug interactions with non-vitamin K antagonist oral anticoagulants: implications for patients with atrial fibrillation. Expert Opin Drug Metab Toxicol. 2015; 11: 937–948. https://doi.org/10.1517/17425255.2015.1027683 PMID: 25791767

74. Jackevicius CA, Tsadok MA, Essebag V, Atzema C, Eisenberg MJ, Tu J V, et al. Early Non-persistence with dabigatran and rivaroxaban in patients with atrial fibrillation. Heart. 2017; 1: 1–8. https://doi.org/10.1136/heartjnl-2016-310672 PMID: 28286333

75. Forslund T, Wettemark B, Hjemdahl P. Comparison of treatment persistence with different oral anticoagulants in patients with atrial fibrillation. Eur J Clin Pharmacol. 2016; 72: 329–338. https://doi.org/10.1007/s00228-015-1983-z PMID: 26613954

76. Horstmann S, Rizos T, Saribas M, Ethyhmieu E, Rauch G, Veltkamp R. Cognitive Impairment is Not a Predictor of Failure to Adhere to Anticoagulation of Stroke Patients with Atrial Fibrillation. Cerebrovasc Dis. 2015; 39: 325–331. https://doi.org/10.1159/000381728 PMID: 25966900

77. Hellwig S, Gritter U, Audebert H, Endres M, Haeseler KG. Non-vitamin K-dependent oral anticoagulants have a positive impact on ischaemic stroke severity in patients with atrial fibrillation. Europace. 2017; 1: 1–6. https://doi.org/10.1093/europace/eu133

78. Alberts MJ, Peacock WF, Fields LE, Bunz TJ, Nguyen E, Milentijevic D, et al. Association between once- and twice-daily direct oral anticoagulant adherence in nonvalvular atrial fibrillation patients and rates of ischemic stroke. Int J Cardiol. Elsevier Ireland Ltd; 2016; 215: 11–13. https://doi.org/10.1016/j.ijcard.2016.03.212 PMID: 27104919

79. Heidbuchel H, Vrijens B, Gross R, Andrade A, Lalama C, Eshleman S. Non-vitamin K antagonist oral anticoagulants (NOAC): considerations on once- vs. twice-daily regimens and their potential impact on medication adherence. European. Oxford University Press; 2015; 17: 1317–1318. https://doi.org/10.1093/europace/eu247 PMID: 26045506

80. Kirchhof P, Radaideh G, Kim YH, Lanas F, Haas S, Amarenco P, et al. Global Prospective Safety Analysis of Rivaroxaban. J Am Coll Cardiol. 2018; 72: 141–153. https://doi.org/10.1016/j.jacc.2018.04.058 PMID: 29976287

81. Seiffge DJ, Polymeris AA, Fladt J, Lyer PA, Engelter ST, De Marchis GM. Management of patients with stroke treated with direct oral anticoagulants. J Neurol. Springer Berlin Heidelberg; 2018;0: 0. https://doi.org/10.1007/s00415-018-9061-y PMID: 30293111

82. Tsiogoulis G, Saffouris A. Intravenous Thrombolysis in Acute Ischemic Stroke Patients Pretreated with Non-Vitamin K Antagonist Oral Anticoagulants. Stroke. 2017; 48: 2021–2033. https://doi.org/10.1161/STROKEAHA.117.017206 PMID: 28536167

83. Suzuki K, Aoki J, Sakamoto Y, Abe A, Suda S, Okubo S, et al. Low risk of ICH after reperfusion therapy in acute stroke patients treated with direct oral anti-coagulant. J Neurol Sci. Elsevier B.V; 2017; 379: 207–211. https://doi.org/10.1016/j.jns.2017.06.004 PMID: 28716241

84. Jin C, Huang RJ, Peterson ED, Laskowitz DT, Hernandez AF, Federspiel JJ, et al. Intravenous IFA (Tissue-Type Plasminogen Activator) in Patients With Acute Ischemic Stroke Taking Non–Vitamin K Antagonist Oral Anticoagulants Preceding Stroke. Stroke. 2018; 49: 2237–2240. https://doi.org/10.1161/STROKEAHA.118.022128 PMID: 30354981

85. Steiner T, Böhm M, Dichgans M, Diener HC, El I, Endres M, et al. Recommendations for the emergency management of complications associated with the new direct oral anticoagulants (DOACs), apixaban, dabigatran and rivaroxaban. Clin Res Cardiol. 2013; 102: 399–412. https://doi.org/10.1007/s00392-013-0560-7 PMID: 23669868
86. Touzé E, Gruel Y, Gouin-Thibault I, De Maistre E, Susen S, Sie P, et al. Intravenous thrombolysis for acute ischemic stroke in patients on direct oral anticoagulants. Eur J Neurol. 2018; 25: 747–e52. https://doi.org/10.1111/ene.13582 PMID: 29360254

87. Liu M, Zheng Y, Li G. Safety of Recanalization Therapy in Patients with Acute Ischemic Stroke Under Anticoagulation: A Systematic Review and Meta-Analysis. J Stroke Cerebrovasc Dis. Elsevier Inc.; 2018; 27: 2296–2305. https://doi.org/10.1016/j.jstrokecerebrovasdis.2018.04.012 PMID: 30017747

88. Rybinnik I, Mullen MT, Messe S, Kasner SE, Cucchiara B. Treatment of acute stroke in patients on Dabigatran: A survey of US stroke specialists. J Stroke Cerebrovasc Dis. Elsevier Ltd; 2013; 22: 1312–1316. https://doi.org/10.1016/j.jstrokecerebrovasdis.2012.12.005 PMID: 23313461

89. Vornicu O, Larock A-S, Dincq A-S, Dufour J, Dogné J-M, Mullier F, et al. Idarucizumab for the treatment of hemorrhage and dabigatran reversal in patients requiring urgent surgery or procedures. Expert Opin Biol Ther. 2017; 17: 1275–1296. https://doi.org/10.1080/14712598.2017.1349749 PMID: 28728489

90. Volbers B, Köhlmann M, Kallmünzer B, Kurka N, Breuer L, Ringwald J, et al. Dabigatran Plasma Levels in Acute Cerebrovascular Events. J Stroke Cerebrovasc Dis. 2016; 25: 877–882. https://doi.org/10.1016/j.jstrokecerebrovasdis.2015.12.024 PMID: 26809705

91. Tse DM, Young L, Ranta A, Barber P. Intravenous alteplase and endovascular clot retrieval following reversal of dabigatran with idarucizumab. JNNP. 2017; 1–2. https://doi.org/10.1136/jnnp-2017-316449 PMID: 26986468

92. Tomita H, Hagii J, Metoki N, Saito S, Shiroto H, Hitomi H, et al. Severity and Functional Outcome of Patients with Cardioembolic Stroke Occurring during Non-vitamin K Antagonist Oral Anticoagulant Treatment. J Stroke Cerebrovasc Dis. W.B. Saunders; 2015; 24: 1430–1437. https://doi.org/10.1016/j.jstrokecerebrovasdis.2015.03.004 PMID: 25843224

93. Tabata E, Yasaka M, Wakugawa Y, Okada Y. Recombinant Tissue type Plasminogen Activator (rt-PA) Therapy in an Acute Stroke Patient Taking Dabigatran Etxilate: A Case Report and Literature Review. Intern Med. 2014; 53: 2013–2015. https://doi.org/10.2169/intem

94. Stöllberger C, Finsterer J. Presentation, therapy and outcome of patients with ischemic stroke under new oral anticoagulants. Neurrol Neurochir Pol. 2014; 48: 136–140. https://doi.org/10.1016/j.pjns.2014.03.001 PMID: 24821640

95. Shahjoei S, Tsvigoulis G, Shahripour RB, Morgan Jones G, Alexandrov A V, Zand R. Safety of Intravenous Thrombolysis among Stroke Patients Taking New Oral Anticoagulants—Case Series and Systematic Review of Reported Cases. J Stroke Cerebrovasc Dis. 2015; 24: 2685–2693. https://doi.org/10.1016/j.jstrokecerebrovasdis.2015.07.021 PMID: 26542821

96. Seiffge DJ, Traenka C, Polymeris A, Hert L, Fisch U, Peters N, et al. Feasibility of rapid measurement of Rivaroxaban plasma levels in patients with acute stroke. J Thromb Thrombolysis. 2017; 43: 112–116. https://doi.org/10.1007/s11239-016-1431-7 PMID: 27696335

97. Bluecher A, Dos Santos SM, Ferreirós N, Labocha S, Meyer Dos Santos IM, Picard-Willems B, et al. Microfluidic coagulation assay for monitoring anticoagulant therapy in acute stroke patients. Thromb Haemost. 2017; 117: 519–528. https://doi.org/10.1160/TH16-08-0619 PMID: 28124061

98. Hoyer C, Filipov A, Neumair-Probst E, Szabo K, Ebert A, Alonso A. Impact of pre-admission treatment with non-vitamin K oral anticoagulants on stroke severity in patients with acute ischemic stroke. J Thromb Thrombolysis. Springer US; 2018; 45: 529–535. https://doi.org/10.1007/s11239-018-1634-1 PMID: 29476304

99. Purrucker JC, Wolf M, Haas K, Siedler T, Rizos T, Khan S, et al. Microbleeds in ischemic vs hemorrhagic strokes on novel oral anticoagulants. Acta Neurol Scand. 2018; 138: 163–169. https://doi.org/10.1111/ane.12934 PMID: 29663313

100. Shin H, Cho MC, Kim RB, Kim CH, Choi NC, Kim SK, et al. Laboratory measurement of apixaban using anti-factor Xa assays in acute ischemic stroke patients with non-valvular atrial fibrillation. J Thromb Thrombolysis. Springer US; 2018; 45: 250–256. https://doi.org/10.1007/s11239-017-1590-1 PMID: 29198080

101. Altay S. New oral anticoagulants-TURKey (NOAC-TURK): Multicenter cross-sectional study. Anatol J Cardiol. 2017; 353–361. https://doi.org/10.14744/AnatolJCardiol.2016.7472 PMID: 28100898